

SUB
(c) 7-10 μm to target upper airways of the respiratory tract; and
further wherein aerosol volume inhaled is controlled along with free air volume inhaled prior to
and following inhalation of aerosol; and
still further wherein aerosol particles are comprised of a polynucleotide and a condensing agent
which results in condensing polynucleotide particles to a size in a range of from about 20 to 50
nanometers, thereby delivering the particles of aerosol to a targeted area of the patient's respiratory tract.

FE
58. (New) The method of claim 57, wherein the particle size is adjusted such that the
aerodynamic diameter of the particles is in a range of from 1-3 μm .

59. (New) The method of claim 57, wherein the particle size is adjusted such that the
aerodynamic diameter of the particles is in a range of from 4-6 μm .

1
D 60. (New) The method of claim 57, wherein the particle size is adjusted such that the
aerodynamic diameter of the particles is in a range of from 7-10 μm .

61. (New) The method as claimed in claim 58, wherein the aerosol particles are further
comprised of a cationic lipid.

62. (New) The method as claimed in claim 61, wherein the cationic lipid is selected from the
group consisting of DOTMA, DOTAP and DC-Chol.

63. (New) The method as claimed in claim 57, wherein the condensing agent is selected
from the group consisting of protamine sulfate, polylysine, and combinations thereof.

64. (New) The method as claimed in claim 57, wherein the condensing agent is protamine
sulfate.

65. (New) The method as claimed in claim 64, wherein the polynucleotide and protamine
sulfate are present in a weight ratio of from about 2:1 to about 1:11.

SUB
FE 66. (New) The method as claimed in claim 57, wherein the condensing agent is

sub
ed
dextran sulfate.

67. (New) The method as claimed in claim 57, wherein the condensing agent is a polyamine.

68. (New) The method as claimed in claim 67, wherein the polyamine is selected from the group consisting of spermine, spermidine and putrescine.

✓
69. (New) The method as claimed in claim 57, wherein the condensing agent is selected from the group consisting of poly-lysine and poly-ethyleneimine.

①
70. (New) The method of claim 57, further comprising:
adjusting the patient's inspiratory flow rate inside a range of about 0.10 to about 4.0
liters/second.

71. (New) The method of claim 70, wherein the flow rate is adjusted inside a range of about 0.2 to about 3.0 liters per second.
